For the study, the team collected blood samples from 40 children with peanut allergies before, during and after ingesting incremental amounts of peanuts at 20-minute intervals. The participants did the same with a placebo — oat powder — on a separate day.
The team’s goal for the study was to compare the children’s gene expression over the course of their allergic reaction. To do so, the researchers analyzed RNA sequencing data from their blood samples, identifying six genes that activated hundreds of other genes in children experiencing a severe reaction.
“This study highlights genes and molecular processes that could be targets for new therapies to treat peanut-allergy reactions and could be important to understanding how peanut allergy works overall,” said senior author, Supinda Bunyavanich, MD, an associate professor of pediatrics and genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai.
More articles on data analytics & precision medicine:
Intermountain Healthcare issues $3M in seed funding to hospital workflow startup
Why this STD testing provider is expanding into at-home specialty & wellness diagnostics
5 questions with Amplefi OPS founder John D’Alesandro on painting a ‘forward picture’ of hospital operations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.